Algernon Pharmaceuticals Inc Class A AGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AGN is a good fit for your portfolio.
News
-
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
-
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
-
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
-
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Trading Information
- Previous Close Price
- CAD 0.10
- Day Range
- CAD 0.10–0.10
- 52-Week Range
- CAD 0.05–0.30
- Bid/Ask
- CAD 0.10 / CAD 0.12
- Market Cap
- CAD 2.16 Mil
- Volume/Avg
- 2,200 / 31,509
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1
Valuation
|
Metric
|
AGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AGN
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.04 |
Interest Coverage | — |
Quick Ratio
AGN
Profitability
|
Metric
|
AGN
|
|---|---|
Return on Assets (Normalized) | −57.30% |
Return on Equity (Normalized) | −108.66% |
Return on Invested Capital (Normalized) | −108.74% |
Return on Assets
AGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zjrbmrgck | Bxzy | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ngmjnzgz | Wqjkcl | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bjwrkfczx | Wlddxl | $98.8 Bil | |
MRNA
| Moderna Inc | Ywxyxwssd | Lhsb | $38.8 Bil | |
ARGX
| argenx SE ADR | Ybtdgpxp | Kkrm | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Zgttyddx | Sxxg | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rqztxrxtj | Lvltqfl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jbnmmlhkw | Fqlcdy | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kzbwwsqh | Lpfzhvy | $12.4 Bil | |
INCY
| Incyte Corp | Tjmtnnm | Rfdmlj | $11.9 Bil |